Skip to content

Non-invasive PGT-A (niPGT-A)

Chromosome screening from the embryo’s culture fluid, used alongside, not instead of, biopsy PGT-A.

Key facts

Sample
Spent embryo culture medium
Method
NGS of embryonic cell-free DNA
Price
On request
Register your clinicBack to the test menu

About this test

Analyses embryonic cell-free DNA in spent culture medium as a biopsy-free adjunct to, not a replacement for, trophectoderm-biopsy PGT-A.

What the report contains

Biopsy-free aneuploidy screen per embryo (investigational).

Evidence and limitations

Evidence: PGT-M/SR established; PGT-A used selectively

PGT-M and PGT-SR are well-established for monogenic disease and structural rearrangements. PGT-A and non-invasive PGT-A are best used selectively, with the clearest signal in older patients per transfer.

Limitations

Randomised trials have not shown PGT-A to improve cumulative live birth in unselected patients: it selects between existing embryos rather than improving them. niPGT-A from spent culture medium is investigational, and its concordance with trophectoderm biopsy varies between laboratories.

PGT and embryo testing: published evidence

Ordering and consent

This test needs genetic counselling and written consent; your clinic confirms both at ordering.

More in Embryo testing (PGT)

  • PGT-A

    Screens embryos for the right number of chromosomes before transfer.

  • PGT-SR

    For carriers of chromosome rearrangements; finds the balanced embryos.

Register your clinic

Registration includes onboarding and training for your team. We reply within two working days.

Register your clinic